FLP
STOK icon

Financial Life Planners’s Stoke Therapeutics STOK Stock Holding History

Financial Life Planners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.71K Hold
144
– – ﹤0.01% 266
2026
Q1 		$4.69K Buy
+144
New +$4.72K ﹤0.01% 269

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
GIM
Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Financial Life Planners's STOK Position: Q2 2026 in Review

Financial Life Planners held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 144 shares worth $4.71K. The position accounts for ﹤0.01% of the portfolio, ranked #266.

Financial Life Planners first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Financial Life Planners held 144 shares of Stoke Therapeutics worth $4.71K as of Q2 2026.
  • Financial Life Planners left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Financial Life Planners's portfolio in Q2 2026, its #266 holding.
  • Financial Life Planners first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Financial Life Planners's 13F filing for Q2 2026, filed 21 Jul 2026.